The Autogenous Vaccines Market refers to the production and distribution of vaccines that are custom-made for individual animals or groups of animals. These vaccines are produced from the pathogens that have been isolated from the animals and therefore are specifically designed to protect against the unique strains of pathogens that are prevalent in a particular geographic region or population of animals. The market for autogenous vaccines is rapidly growing due to the increasing demand for effective animal healthcare and the need for customized vaccination solutions.
Drivers of the Autogenous Vaccines Market
The primary driver of the autogenous vaccines market is the growing demand for effective animal healthcare. As the world’s population continues to grow, the demand for food products is also increasing, which in turn is driving the demand for healthy and disease-free animals. Additionally, the rise in the incidence of zoonotic diseases such as avian influenza, swine flu, and COVID-19 has highlighted the need for effective animal disease control measures.
Another driver of the autogenous vaccines market is the increasing adoption of customized vaccination solutions. Autogenous vaccines offer several advantages over traditional vaccines, including increased effectiveness, reduced risk of adverse reactions, and greater flexibility in terms of dosages and delivery schedules. Additionally, autogenous vaccines can be customized to meet the specific needs of individual animals or populations, which can help to improve overall animal health and productivity.
Competition Landscape
There are both worldwide and regional market players in the autogenous vaccines industry. Leading companies emphasize inorganic expansions as one of their primary growth strategies in order to maintain market competitiveness. Additionally, industry participants are working to increase their local and international reach through mergers and acquisitions.
Key instances include:
In Jan 2020, Innoject Pro was a newly developed subcutaneous chick vaccination technology that was unveiled by Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, New Jersey, USA, and Automazioni VX Inc.
In Sep 2020, at its French facility, Ceva Santé Animale tripled its ability to produce bacterial autogenous vaccines, especially for pigs and poultry.